Interim report January

Interim report January - March 2010

Continuous strong underlying growth with good profitability and cash flow



•	Growth in local currency was 15 percent. Sales amounted to SEK 75 (72)
million, corresponding to an increase of 5 percent in SEK.

•	Operating income before research and development costs increased by 21 percent
and amounted to SEK 21 (17) million.

•	Operating income (EBIT) increased by 14 percent and amounted to SEK 10 (9)
million. The operating margin was 13 (12) percent. 

•	The Group's net income amounted to SEK 10 (8) million, which gives earnings
per share of SEK 0.50 (0.43)

•	The cash flow from operating activities was SEK 7 (-3).

•	The clinical study on STEEN Solution™ was completed during the period.

•	A collaboration agreement was entered into with Finn-Medi Research Ltd
concerning the Stem Cells area.


April 27, 2010
Gothenburg

Magnus Nilsson
CEO


Queries should be addressed to: 
Magnus Nilsson, CEO; phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13

________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 170 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan.
Production facilities are located in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
_________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
Tuesday April 27, 2010 at 8:30 am CET.

This is a translation of the Swedish version of the notice. When in doubt, the
Swedish wording prevails.
Interim report January - March 2010

Attachments
